Waters (WAT) Q2 2025: Recurring Revenue Jumps 11% as Pharma Replacement Cycle Accelerates
Waters delivered robust Q2 results, powered by double-digit recurring revenue growth and strong pharma demand, while maintaining disciplined execution ahead of its transformative BD acquisition. Management’s guidance raise reflects confidence in commercial momentum, but margin pressures and macro-sensitive segments temper the outlook. The forthcoming BD integration brings major synergy potential, but also execution complexity and new competitive dynamics for the combined business.
Summary
- Pharma Replacement Cycle Drives Outperformance: Large pharma and CDMO demand fueled instrument and service growth.
- Margin Pressures from Tariffs and Mix: Gross margin dilution and regional shifts offset some operational gains.
- BD Acquisition Synergies in Focus: Integration playbook targets commercial and operational uplift, but execution risk rises.
Performance Analysis
Waters posted another above-guidance quarter, with sales up 9% as reported and 8% in constant currency. Recurring revenue led the way, growing 11% year-over-year, driven by 9% service growth and a 16% increase in chemistry, though chemistry benefited from an $8 million pull-forward tied to tariff timing. Excluding this, underlying growth rates remained strong, with chemistry up 10% and overall constant currency growth at 7%.
Instruments sales grew mid-single digits, led by high single-digit growth in liquid chromatography (LC) and mass spectrometry (MS) platforms. The Alliance IS instrument saw standout 300% growth, while the Zivo TQ Absolute XR exceeded expectations and enabled new wins in demanding DMPK labs. Segment-wise, pharma led with 11% growth, while industrial rose 6%. Academic and government declined 3%, but fared better than anticipated.
- Geographic Mix and Tariffs Weigh on Margins: Operating margin came in at 29.1%, pressured by regional sales mix and tariff-related costs.
- China and India Outperform: Double-digit growth in China and high teens in India, supported by local innovation and stimulus tailwinds.
- TA Division Softness: Macro-sensitive polymer and materials testing in the Americas and Europe led to a 6% TA decline, with the US down roughly 20%.
Free cash flow reached $159 million, and management is prioritizing debt paydown and cash accumulation ahead of the BD transaction. The company raised its full-year constant currency sales growth and EPS guidance, reflecting strong order momentum and commercial execution.
Executive Commentary
"This performance reflects strong execution, revitalized innovation, and our successful expansion into higher growth areas. Three strategic pillars we set in motion five years ago and continue to deliver with strength and resilience."
Dr. Udit Batra, President and Chief Executive Officer
"Orders outpaced sales, reflecting solid momentum and setting us up well for further strength in the second half of the year. Our operating tax rate came in at 17.9% due to jurisdictional mix and discrete items specific to the quarter, creating a 5 cent headwind to adjusted EPS."
Amol Charbul, Senior Vice President and Chief Financial Officer
Strategic Positioning
1. Pharma and CDMO Replacement Cycle Strength
Waters’ core pharma business continues to capitalize on a robust replacement cycle, particularly among large pharma and contract development and manufacturing organizations (CDMOs, outsourced pharma manufacturing partners). The company’s revitalized instrument portfolio, including the Alliance IS and TQ Absolute XR, is driving both replacement and share gains, especially as new product launches address evolving customer needs in regulated QAQC (quality assurance/quality control) environments.
2. Commercial Execution and KPI Discipline
Waters’ operational rigor is evident in its KPI-driven commercial model, with service plan attachment rates rising 200 basis points to 52% and e-commerce adoption surpassing 40% of chemistry revenue. These levers not only boost recurring revenue but also serve as a template for the upcoming BD integration, where similar underpenetration in service and digital channels presents substantial uplift potential.
3. Innovation and Adjacency Expansion
Product innovation remains a differentiator, with the launch of BioResolve Protein A affinity columns (bioseparations, specialized columns for large molecule analysis) and the rapid adoption of Zivo TQ Absolute XR. Waters is also targeting high-growth adjacencies such as PFAS and GLP testing, both up 50%+ year-over-year, and leveraging its Empower software platform for new analytical modalities.
4. BD Acquisition Synergy Blueprint
The planned acquisition of BD’s Biosciences and Diagnostic Solutions business is set to transform Waters’ scale and market reach, with management targeting $345 million in EBITDA synergies (cost and revenue) by year five. The integration playbook focuses on instrument replacement, e-commerce, service attachment, and cross-selling into underpenetrated pharma and diagnostics channels. Notably, none of the upside from microbiology margin expansion or new mass spec applications is included in the base case, providing potential for future outperformance if executed well.
5. Margin Structure and Cost Management
Despite strong top-line growth, margin pressures persist, with gross margin diluted by tariffs and regional mix. Management’s track record of rapid cost action (e.g., 5% headcount reduction in 2023) underpins confidence in synergy delivery, but the combined company’s margin trajectory will depend on successful integration and realization of operational efficiencies, especially in the microbiology business.
Key Considerations
Waters’ Q2 results highlight the company’s ability to execute in core markets while positioning for transformative change through the BD acquisition. The following considerations frame the strategic context for investors:
Key Considerations:
- Recurring Revenue Flywheel: High service and chemistry attachment rates drive predictability and margin resilience, especially as e-commerce penetration deepens.
- China and India Resurgence: Localized innovation and stimulus support strong growth, but management is prudent in back-half assumptions given macro and policy uncertainty.
- TA Segment Vulnerability: Materials and polymer testing remains macro-sensitive, with US TA down 20%, highlighting end-market cyclicality.
- Synergy Realization Risk: The BD integration brings substantial revenue and cost synergy potential, but execution risk is elevated given the scale and operational complexity.
- Tariff and Margin Volatility: Tariff dynamics pulled forward chemistry demand and pressured margins; future shifts could impact both revenue timing and profitability.
Risks
Waters faces several risks as it enters the next phase: Margin pressures from tariffs and regional mix may persist, especially if trade policy shifts further or if macro headwinds deepen in industrial and academic segments. The BD integration introduces significant execution and cultural risk, with synergy realization dependent on rapid operational alignment. Finally, competitive intensity in both core and adjacent markets could challenge Waters’ ability to sustain above-market growth, particularly if innovation cycles slow or integration distracts commercial teams.
Forward Outlook
For Q3 2025, Waters guided to:
- Constant currency sales growth of 5% to 7%
- Adjusted EPS of $3.15 to $3.25 (8% to 11% growth)
For full-year 2025, management raised guidance:
- Constant currency sales growth of 5.5% to 7.5%
- Adjusted EPS of $12.95 to $13.05 (9% to 10% growth)
Management highlighted several factors that shape the outlook:
- Strong pharma and CDMO replacement cycle momentum, with order funnels robust across geographies
- Conservative assumptions for China and academic/government funding, despite recent upside
- Tariff impact held steady in guidance, with potential for modest EPS upside if rates remain stable
Takeaways
Waters’ commercial momentum and innovation engine remain intact, but the business is entering a period of heightened complexity and integration risk as it prepares for the BD combination.
- Recurring Revenue and Pharma Demand Anchor Growth: Service and chemistry outperformance, coupled with robust pharma replacement cycles, provide a resilient foundation.
- Margin and Macro Sensitivities Persist: Tariff headwinds, regional mix, and TA segment softness will require ongoing cost vigilance and operational agility.
- BD Integration Is the Next Big Test: Execution on synergy capture and operational alignment will determine the long-term value creation trajectory for the combined entity.
Conclusion
Waters delivered a strong Q2 with recurring revenue and pharma-led growth, but faces a critical transition as it prepares to integrate BD’s biosciences and diagnostics assets. The company’s disciplined execution and innovation track record provide a solid base, but the path forward will hinge on successful synergy realization and margin management amid ongoing industry and macro volatility.
Industry Read-Through
Waters’ results and commentary signal that the pharma analytical tools market remains robust, especially in regulated QAQC and CDMO segments. Recurring revenue models anchored by service and consumables are proving resilient, while innovation in LC-MS and bioseparations is driving competitive differentiation. The BD acquisition underscores a sector-wide push for scale and portfolio breadth, with cross-selling and digital channel penetration emerging as key value levers. However, margin pressures from tariffs and regional mix, as well as execution risk in large integrations, are likely to be recurring themes for peers navigating similar transformations.